🇺🇸 FDA

Drug profile · INN

febuxostat

ADENURIC

approved M04AA03
US status
approved
Patents linked
5
News articles
0

Quick answer

febuxostat (ADENURIC) is an FDA-listed pharmaceutical active ingredient. Associated with Sunshine Biopharma. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN febuxostat
Brand ADENURIC
Route ORAL
Formulation TABLET
ATC code M04AA03
Originator Sunshine Biopharma

Related patents

Search patents →

  1. US 9107912

    Methods for concomitant treatment of theophylline and febuxostat

    Expires Mon Aug 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8742129

    Crystalline forms of febuxostat

    Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8609856

    Crystalline forms of Febuxostat

    Expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8415481

    Crystalline form of febuxostat

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8372872

    Methods for concomitant treatment of theophylline and febuxostat

    Expires Mon Feb 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is febuxostat?

febuxostat (ADENURIC) is an FDA-listed pharmaceutical active ingredient. Associated with Sunshine Biopharma. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for febuxostat?

ADENURIC is a marketed brand name for febuxostat. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of febuxostat?

febuxostat has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.